mRNA-delivery of IDO1 suppresses T cell-mediated autoimmunity

Laurie L Kenney,Rebecca Suet-Yan Chiu,Michelle N Dutra,Alexandra Wactor,Chris Honan,Lukas Shelerud,Joshua J Corrigan,Kelly Yu,Joseph D Ferrari,Kate L Jeffrey,Eric Huang,Paul L Stein
DOI: https://doi.org/10.1016/j.xcrm.2024.101717
2024-08-30
Abstract:Indoleamine-2,3-dioxygenase (IDO)1 degrades tryptophan, obtained through dietary intake, into immunoregulatory metabolites of the kynurenine pathway. Deficiency or blockade of IDO1 results in the enhancement of autoimmune severity in rodent models and increased susceptibility to developing autoimmunity in humans. Despite this, therapeutic modalities that leverage IDO1 for the treatment of autoimmunity remain limited. Here, we use messenger (m)RNA formulated in lipid nanoparticles (LNPs) to deliver a human IDO1 variant containing the myristoylation site of Src to anchor the protein to the inner face of the plasma membrane. This membrane-anchored IDO1 has increased protein production, leading to increased metabolite changes, and ultimately ameliorates disease in three models of T cell-mediated autoimmunity: experimental autoimmune encephalomyelitis (EAE), rat collagen-induced arthritis (CIA), and acute graft-versus-host disease (aGVHD). The efficacy of IDO1 is correlated with hepatic expression and systemic tryptophan depletion. Thus, the delivery of membrane-anchored IDO1 by mRNA suppresses the immune response in several well-characterized models of autoimmunity.
What problem does this paper attempt to address?